Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Vigonvita Life Sciences Co., Ltd.
蘇州旺山旺水生物醫藥股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2630)

CHANGE OF THE TRUSTEE OF H SHARE AWARD SCHEME

Reference is made to the announcement of Vigonvita Life Sciences Co., Ltd. (the "**Company**") dated February 9, 2026 in relation to the proposed adoption of the Share Award Scheme (the "**Announcement**"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as defined in the Announcement. The Board is pleased to announce that on March 2, 2026, in order to optimize the management efficiency and operational arrangements of the Share Award Scheme, the Company proposed the change of the Trustee of the Share Award Scheme adopted by the Company on February 9, 2026. The Share Award Scheme shall take effect upon the consideration and approval of the Shareholders which will be sought at the EGM.

The Company engaged JLT Trust (Hong Kong) Limited as the Trustee with effect from March 2, 2026 to replace Futu Trustee Limited, which shall cease to act as the Trustee.

Futu Trustee Limited confirmed that it has no disagreement with the Company, and there is no matter relating to the change of the Trustee that needs to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited.

Save for the change of the Trustee, all information as set out in the scheme rules of the Share Award Scheme remains unchanged.

By order of the Board
Vigonvita Life Sciences Co., Ltd.
Dr. Tian Guanghui
Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager

Hong Kong, March 2, 2026

As at the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.